Who We Are
The Translational Medicine Group serves to connect academia and industry to identify synergies, provide strategic advice, and support the development of novel therapeutics. We leverage the assets of the Boston biomedical community and create cross-functional teams under the guidance of an executive leadership team with a thorough understanding of the drug development process and the best practices of both academia and industry.
Mason W. Freeman, M.D., Center Director & FounderPhone: 617-724-7704
Dr. Freeman graduated from Harvard College and received his M.D. at the University of California, San Francisco. He served as an intern, resident, endocrinology fellow, and Chief Resident in Medicine in the Department of Medicine at the Massachusetts General Hospital. He trained as a post-doctoral research fellow in the Biology Department of the Massachusetts Institute of Technology, where he played a central role in cloning the first macrophage scavenger receptor to be molecularly identified. He became Chief of the Lipid Metabolism Unit at the MGH in 1992 and continues to direct that Unit as well as the Translational Medicine programs of both the MGH Center for Computational and Integrative Biology and the MGH Clinical Research Division. From 2005-2007, while on a leave of absence from Harvard, he served as a head of the Novartis Translational Medicine program for Cardiovascular & Metabolic Diseases as well as the company’s Global Head of Biomarker Development. Dr. Freeman has served as a consultant to multiple life science startup companies either independently or through his role as a venture partner at 5AM Ventures, an early-stage life science venture firm. At 5AM, he has contributed to the creation of over 30 companies, serving on the boards of Crinetics and Envoy Therapeutics, a neuroscience company acquired by Takeda in 2012. Dr. Freeman also played a key medical advisor role at Relypsa, which developed the first chronic oral therapy for hyperkalemia approved by the FDA in over 50 years. Dr. Freeman is a Professor of Medicine at Harvard Medical School and editor of the Adult Primary Care lipid section of UpToDate, one of the world’s most widely read and cited on-line medical textbooks.
Brian Seed, Ph.D., FounderPhone: 617-726-5975
Dr. Seed is a Professor of Genetics at Harvard and Director of the Center for Computational and Integrative Biology at the Massachusetts General Hospital (MGH). He obtained his B.S. and Ph.D. degrees from the California Institute of Technology. Prof. Seed has published widely in the field of genetics and molecular biology with an emphasis on the development of methods and technology. His early efforts to develop genetic selections for transiently expressed genes led to the identification of cDNAs encoding the majority of the then-recognized lineage antigens of the immune system. In addition he has made several contributions to the understanding of the mechanisms of T cell activation. His work on immunoglobulin fusion proteins led to the identification of several co-receptors and ligands and laid the basis for the development of several therapeutic fusion proteins that conceptually underlies much of the current biologics effort in the pharmaceutical industry. It was this work that led to the creation of etanercept (Enbrel®), one of the most successful biologic therapeutics of the past two decades. Dr. Seed has co-founded several biotech companies, including Connetics, Edge Biosystems, Phylos, and Egret Pharma (Shanghai) Ltd. and has served on advisory boards for Hoechst/Aventis, Medigene A.G., St. Jude Children’s Research Hospital, Phylos and New Leaf Ventures. Dr. Seed holds approximately 50 patents or pending patent applications.
Yuan-Di Halvorsen, Ph.D., Chief Operating OfficerPhone: 617-726-4236
Dr. Halvorsen joined the Translational Medicine program of the Center for Computational and Integrative Biology at MGH in 2007. She has established the group’s core competencies in program management, regulatory and clinical operations, and implemented Quality Assurance systems within this academic enterprise. By applying these management tools and leveraging the research and clinical knowledge of MGH faculty members, the Translational Medicine program has advanced multiple therapeutic development projects in an effective, efficient and economical manner. Through her leadership, TMG has successfully advanced both small molecules and biologics from basic research discovery labs to the clinic. These programs have ranged widely, including new therapies for diabetes, depression, respiratory papillomatosis, and anemia. Earlier stage programs in cholera vaccine development and stroke therapy are also ongoing. Dr. Halvorsen also advises academic investigators and biotechnology companies on new drug development, including regulatory and clinical strategy. Prior to her work at the MGH, Dr. Halvorsen co-founded two biotechnology companies with platform technologies in cell-based therapy and led the clinical development of protein and antibody drugs for cancer and supportive care for cancer patients. She served as Associate Director of Clinical Development at CuraGen Corporation, Vice President of Research at Artecel Sciences, and Vice President of Research & Development and President of Zen-Bio, Inc. In addition, Dr. Halvorsen was an Adjunct Associate Professor at the University of North Carolina at Greensboro. She obtained her Ph.D. in Biochemistry at the University of Kentucky and received postdoctoral training at the Dana Farber Cancer Institute and Harvard Medical School.
Rajesh Ranganathan, PhD, Director of Translational Medicine Initiatives and Clinical Partnerships
Dr. Rajesh Ranganathan is the Director of Translational Medicine Initiatives and Clinical Partnerships at Massachusetts General Hospital (MGH), Boston. In this role, Dr. Ranganathan will conduct business development that will culminate in clinical studies being conducted at the Translational Research Center at MGH. He will also contribute to Translational Research Training programs to be offered to a range of trainees. Additionally, Dr. Ranganathan will also build partnerships within and external to MGH, including industry, to conduct preclinical research to elucidate the causes of serious and perplexing ailments that defy a definitive diagnosis or are refractory to existing treatments. Previously, he served for one year as the Vice President of Science and Regulatory Advocacy at PhRMA (Pharmaceutical Researchers and Manufacturers of America) in Washington DC. Prior to his time at PhRMA, for 3+ years, Dr. Ranganathan was the Director of the Office of Translational Research at the National Institutes for Neurological Disorders and Stroke (NINDS) at the NIH. He transitioned to this role at NINDS after serving as the Senior Advisor to the NIH Director for Translational Medicine for 15 months. He joined the NIH in Nov. 2010 after spending 7+ years at the Novartis Institutes for Biomedical Research Inc. in Cambridge, MA, where he was a Director in the scientific strategy and portfolio management group and also founded and led a Global Office of Scientific Education for the Institutes. Dr. Ranganathan received his Bachelor’s Degrees in Biology and Chemistry from Amherst College, performed his doctoral training with Dr. H. Robert Horvitz at MIT in C. elegans neurobiology, and his postdoctoral training with Dr. Linda Buck at Harvard Medical School and the Fred. Hutchinson Cancer Research Center in the area of mammalian sensory regulation.
Vera J. Martin, BA, Clinical Development Project Leader
Ms. Martin joined the Translational Medicine Group in October 2016. She brings over 27 years of drug development experience in Global Project and Program Management, Clinical Operations, Data Management, Medical Writing, Regulatory Publishing, and Strategic Alliance. Ms. Martin held various positions with increased responsibility at Marion Merrell Dow, ClinTrials Research, Parexel, PPD, and Pharm-Olam International. Most recently, Ms. Martin founded a consulting company that provided program management and clinical development strategy in rare oncology disease and diabetes.
Over Ms. Martin’s career, she has primarily led global teams for large Phase 3 programs within North and South America, Western and Eastern Europe, Asia-Pacific, and Middle-East North-Africa regions. Successful completion of these Phase 3 programs resulted in marketing approval across various therapeutic areas including diabetes, oncology (rare), cardiology, opioids, asthma, migraine, and paroxysmal nocturnal hemoglobinuria. Ms. Martin holds a Bachelor of English from University of Missouri-Kansas City and a Master Certificate in Project Management from Villanova University.
Roger A. Albright, MBA, Senior Clinical Trial Manager
Mr. Albright has worked in the clinical research field for more than 25 years. His expertise includes project management, domestic and international clinical regulations, and clinical data analysis and reporting for medical device and drug studies. Previously Mr. Albright held the position of Director of Clinical Services for Foresight Regulatory Strategies, Inc., a specialty CRO dedicated to ophthalmic device clinical development. Mr. Albright was Sr. Project Manager for Molecular Geodesics (a high technology startup company); Project Manager for Parexel International; Manager of World-Wide Clinical Affairs for Angiodynamics (a small cardiovascular device firm); Clinical Manager for Polymer Technology Corporation (an affiliate of Bausch & Lomb) and has held various clinical research positions at Bausch & Lomb, Inc. Mr. Albright received his B.S. in Marketing from Rochester Institute of Technology and his M.B.A. from Boston University.
Priya Bowden, RAC, Regulatory Operations Manager
Ms. Bowden has been a member of TMG since its inception in 2007. She oversees global regulatory submissions and has extensive experience in regulatory electronic submission publishing, submitting and lifecycle maintenance of INDs. She participates on project development teams to ensure US and other regulatory requirements are met and strategy is implemented. Her role includes the development and maintenance of the quality assurance program at TMG, ensuring staff training, process reviews, corrective action plans and auditing. Prior to her work in regulatory affairs, Ms. Bowden had 10 years experience in public health.
Tara K. Thurber, BS, Director, Vendor Management
Ms. Thurber has been at Massachusetts General Hospital since 2000 and brings years of project and financial management to the TMG. She is responsible for contract negotiation and third-party vendor oversight. She leads global phase 2-3 trials with sites in the US, Europe and Asia Pacific. In addition she has led the design of HIVE, the TMG Clinical Trial Management System web portal and acts as Administrative Director for the MGH Center for Computational and Integrative Biology.
Xiaoyan Li, Ph.D., Project Leader
Dr. Li has over seven years of hands-on working experience in Mass Spectrometry based ADME/DMPK assay development and data analysis to advance drug candidate from drug discovery to Phase I/II clinical studies. Her expertise includes LC-MS/MS, in vitro and in vivo drug metabolism and drug-drug interaction, metabolite structure elucidation and PK modeling. She oversaw and participated in writing for various drugs’ IND filing with both FDA and CFDA. Prior to joining MGH, Dr. Li served as a DMPK leader in pharmaceutical industry and CRO for five years, following which she was a DMPK consultant for two years. She earned her Ph.D. in pharmaceutical analysis at the Shenyang Pharmaceutical University and received two years of post-doctoral training at the University of Georgia in protein analytical chemistry.
Annie L. Conery, Ph.D., Project Leader
Dr. Conery has over 10 years of project management experience and has managed many early drug discovery, preclinical development and clinical operations projects. In addition to her project management role, she provides clinical laboratory expertise and regulatory submissions support for the Translational Medicine Group. She obtained her Ph.D. in Molecular and Cell Biology from the University of California at Berkeley, received further training as a research scientist at Massachusetts General Hospital and Harvard Medical School and has co-authored more than twenty publications throughout the course of her research career.
Allison Corlett Caso, MPH, Regulatory Operations Specialist
Prior to joining the Translational Medicine Group, Allison graduated from Boston University School of Public Health in 2011 with an MPH in Maternal and Child Health from the Department of Community Health Sciences. While attending graduate school Allison was a BUSPH employee contracted through the Department of Veterans Affairs coordinating projects involving primary care and mental health coordination, quality improvement initiatives, and coordination of primary care teams. Prior to that Allison was a research assistant at the Brigham and Women’s Hospital working on the Nurses’ Health Study 1 and 2 and the Growing Up Today Study 1 and 2, longitudinal studies looking at the health of women and their children. Allison received a B.A. from Boston University with a double major in Psychology and English.
Rutu Dabhi, MS, Documentation Specialist
Rutu provides clinical research documentation support to the Translational Medicine Group. Along with her Master’s degree in Clinical Research (graduate year -2015) from Eastern Michigan University, she has experience working in both academic and industrial environments. Prior to joining TMG, she worked as a Clinical Project Coordinator at Merck Pharmaceuticals, providing clinical trials related support to the development team. She has also worked as a Clinical Research Coordinator with psychiatric phase 2 clinical trial experience at the Early Treatment Center, Michigan. There, she provided study recruitment and study management support. During completion of her studies, she also worked as a Clinical Research Coordinator intern with the Oncology clinical study team (phase 2 and 3 solid tumor studies) at the Cancer Center Clinical Trials Office, University of Michigan.